Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE, Fleming GF; Chicago Phase II Consortium; PMH Phase II Consortium; California Phase II Consortium. Nimeiri HS, et al. Among authors: faoro l. Gynecol Oncol. 2008 Jul;110(1):49-55. doi: 10.1016/j.ygyno.2008.02.009. Epub 2008 Apr 18. Gynecol Oncol. 2008. PMID: 18423560 Free PMC article. Clinical Trial.
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
Cohen EE, Subramanian J, Gao F, Szeto L, Kozloff M, Faoro L, Karrison T, Salgia R, Govindan R, Vokes EE. Cohen EE, et al. Among authors: faoro l. Clin Lung Cancer. 2012 Mar;13(2):123-8. doi: 10.1016/j.cllc.2011.10.001. Epub 2011 Nov 18. Clin Lung Cancer. 2012. PMID: 22100149 Clinical Trial.
MET receptor tyrosine kinase.
Faoro L, Cervantes GM, El-Hashani E, Salgia R. Faoro L, et al. J Thorac Oncol. 2009 Nov;4(11 Suppl 3):S1064-5. doi: 10.1097/01.JTO.0000361752.86918.09. J Thorac Oncol. 2009. PMID: 19861919 Free PMC article.
Protein kinase C beta in malignant pleural mesothelioma.
Faoro L, Loganathan S, Westerhoff M, Modi R, Husain AN, Tretiakova M, Seiwert T, Kindler HL, Vokes EE, Salgia R. Faoro L, et al. Anticancer Drugs. 2008 Oct;19(9):841-8. doi: 10.1097/CAD.0b013e32830ce506. Anticancer Drugs. 2008. PMID: 18765998 Free PMC article.
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. Seiwert TY, et al. Among authors: faoro l. Cancer Res. 2009 Apr 1;69(7):3021-31. doi: 10.1158/0008-5472.CAN-08-2881. Epub 2009 Mar 24. Cancer Res. 2009. PMID: 19318576 Free PMC article.
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, Karrison T, Ferguson MK, Husain AN, Faoro L, Vokes EE, Gill PS, Salgia R. Ferguson BD, et al. Among authors: faoro l. PLoS One. 2013 Jul 2;8(7):e67668. doi: 10.1371/journal.pone.0067668. Print 2013. PLoS One. 2013. PMID: 23844053 Free PMC article.
66 results